Trial Drug Increased Sunlight Tolerance in EPP Patient
A daily oral medication for erythropoietic protoporphyria is currently under study with Phase 3 results expected by late 2026.
Updated on Oct. 3, 2026 in Biotech
In July 2025, patient Emily Pearson began a clinical trial for bitopertin, a daily oral medication that improved her sunlight tolerance. Disc Medicine, the manufacturer, published trial data in April 2026 showing the drug successfully lowers levels of protoporphyrin IX.
Why it matters
The drug addresses the root cause of erythropoietic protoporphyria, a condition where genetic mutations trigger the production of excess, light-sensitive protoporphyrin IX molecules. Clinical research aims to prove the therapy can safely reduce these levels in the broader patient population.
Disc Medicine reported that bitopertin functions by lowering the body's synthesis of protoporphyrin IX. Phase 3 trial data, which will provide a definitive benchmark for efficacy across 183 participants, is expected in the final quarter of 2026.
The players
Disc Medicine
A biotechnology firm developing therapies for hematologic and rare diseases, currently focused on pipeline candidates for heme synthesis regulation.
Emily Pearson
A patient diagnosed with erythropoietic protoporphyria who participated in clinical trials for bitopertin.
The details
Bitopertin is an oral medication designed to inhibit the body's production of protoporphyrin IX, a chemical that causes extreme light sensitivity in patients with erythropoietic protoporphyria (EPP). By targeting the molecular pathway responsible for this accumulation in the skin, the drug aims to prevent the painful reactions typically triggered by sun exposure. The clinical trials rely on monitoring protoporphyrin IX concentration levels in the bloodstream as a primary marker for therapeutic efficacy.
Timeline
July 2025: Emily Pearson began taking bitopertin.
October 2025: Pearson completed her first marathon.
April 2026: Disc Medicine published initial clinical trial data.
June 2026: Pearson completed her second marathon.
Q4 2026: Phase 3 clinical trial data is expected.
The Tech Race
The development of bitopertin is a key effort within the current EPP treatment landscape, which has historically lacked effective pharmacological options. Researchers are now racing to provide clinical evidence that can clear the regulatory bar previously established for orphan drug therapies.
The medication is currently limited to participants in the clinical trial and is not yet available to the general public. Interested patients should track the upcoming Q4 2026 data release to see if the drug meets the efficacy benchmarks required for a future regulatory filing.
The takeaway
The success of bitopertin hinges on whether the Phase 3 trial data can demonstrate consistent protoporphyrin IX reduction across a large patient group. Readers should monitor the Q4 2026 trial results to determine if the drug will proceed toward an FDA review process.
What happens next
Disc Medicine expects to release results from the 183-patient Phase 3 clinical trial during the fourth quarter of 2026, which will be a critical data point for the company's regulatory path.
Further reading
For more on emerging therapies in rare disease research, visit our Biotech section.
